Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AADINASDAQ:IMRNNASDAQ:MRSNNASDAQ:RNXT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$1.80+2.3%$1.69$1.21▼$3.81$50.63M0.68260,159 shs200,139 shsIMRNImmuron$1.81-9.8%$5.04$1.50▼$2.87$11.03M1.3812,530 shs12,391 shsMRSNMersana Therapeutics$0.37+1.6%$0.35$0.26▼$2.83$45.60M1.322.59 million shs2.43 million shsRNXTRenovoRx$1.30+4.4%$1.01$0.75▼$1.69$47.36M1.1287,837 shs379,551 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience+2.27%-9.55%+24.14%-29.96%-4.26%IMRNImmuron-6.48%+10.33%+1.23%-6.53%-22.58%MRSNMersana Therapeutics+1.64%+3.57%-4.66%-27.24%-84.75%RNXTRenovoRx+4.44%+6.15%+33.23%+29.51%+1.97%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAADIAadi Bioscience0.6232 of 5 stars1.00.00.00.00.63.31.3IMRNImmuron1.2694 of 5 stars3.53.00.00.00.60.00.0MRSNMersana Therapeutics3.5424 of 5 stars3.51.00.04.12.02.50.0RNXTRenovoRx1.8868 of 5 stars3.53.00.00.01.51.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAADIAadi Bioscience 2.00Hold$1.67-7.41% DownsideIMRNImmuron 3.00Buy$5.00177.01% UpsideMRSNMersana Therapeutics 3.00Buy$5.201,321.15% UpsideRNXTRenovoRx 3.00Buy$7.00440.54% UpsideCurrent Analyst Ratings BreakdownLatest IMRN, MRSN, RNXT, and AADI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025RNXTRenovoRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.005/16/2025MRSNMersana TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $10.005/16/2025MRSNMersana TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.005/15/2025MRSNMersana TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$3.005/6/2025MRSNMersana TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$4.00 ➝ $3.004/28/2025RNXTRenovoRxAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $11.004/4/2025RNXTRenovoRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.003/27/2025RNXTRenovoRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.003/3/2025MRSNMersana TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$4.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAADIAadi Bioscience$25.07M1.77N/AN/A$4.29 per share0.42IMRNImmuron$3.21M3.28N/AN/A$1.46 per share1.24MRSNMersana Therapeutics$34.01M1.34N/AN/A$0.31 per share1.18RNXTRenovoRx$240K197.34N/AN/A($0.28) per share-4.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAADIAadi Bioscience-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%8/5/2025 (Estimated)IMRNImmuron-$4.55MN/A0.00N/AN/AN/AN/AN/AN/AMRSNMersana Therapeutics-$171.67M-$0.59N/AN/AN/A-214.20%-401.37%-38.61%8/12/2025 (Estimated)RNXTRenovoRx-$10.23M-$0.40N/AN/AN/AN/A-205.96%-110.01%8/12/2025 (Estimated)Latest IMRN, MRSN, RNXT, and AADI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025MRSNMersana Therapeutics-$0.21-$0.19+$0.02-$0.19$6.05 million$2.75 million5/15/2025Q1 2025RNXTRenovoRx-$0.08-$0.08N/A-$0.08$0.23 million$0.20 million3/31/2025Q4 2024RNXTRenovoRx-$0.12-$0.13-$0.01-$0.12$0.17 million$0.04 million3/18/2025Q4 2024AADIAadi Bioscience-$0.30-$0.67-$0.37-$0.67$7.45 million$7.24 million3/3/2025Q4 2024MRSNMersana Therapeutics-$0.16-$0.11+$0.05-$0.11$7.71 million$16.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAADIAadi BioscienceN/AN/AN/AN/AN/AIMRNImmuronN/AN/AN/AN/AN/AMRSNMersana TherapeuticsN/AN/AN/AN/AN/ARNXTRenovoRxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAADIAadi BioscienceN/A4.894.54IMRNImmuronN/A5.464.87MRSNMersana Therapeutics13.352.352.35RNXTRenovoRxN/A5.665.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAADIAadi Bioscience52.08%IMRNImmuron0.12%MRSNMersana Therapeutics93.92%RNXTRenovoRx3.10%Insider OwnershipCompanyInsider OwnershipAADIAadi Bioscience37.30%IMRNImmuron7.01%MRSNMersana Therapeutics13.00%RNXTRenovoRx9.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAADIAadi Bioscience4024.70 million15.49 millionOptionableIMRNImmuronN/A5.84 million5.43 millionNot OptionableMRSNMersana Therapeutics150124.63 million108.96 millionOptionableRNXTRenovoRx636.57 million22.30 millionNot OptionableIMRN, MRSN, RNXT, and AADI HeadlinesRecent News About These CompaniesQ2 Earnings Forecast for RenovoRx Issued By HC WainwrightMay 22, 2025 | americanbankingnews.comRenovoRx's (RNXT) "Buy" Rating Reaffirmed at HC WainwrightMay 20, 2025 | americanbankingnews.comEarnings call transcript: RenovoRx Q1 2025 revenue exceeds expectationsMay 17, 2025 | investing.comRenovoRx, Inc. (NASDAQ:RNXT) Q1 2025 Earnings Call TranscriptMay 17, 2025 | msn.comRenovoRx Inc (RNXT) Q1 2025 Earnings Call Highlights: Promising Revenue Growth and Clinical ...May 16, 2025 | finance.yahoo.comLe BPA de RenovoRx a dépassé les attentes, le CA en dessous des prévisionsMay 15, 2025 | fr.investing.comTranscription des résultats : le chiffre d’affaires de RenovoRx au T1 2025 dépasse les attentesMay 15, 2025 | fr.investing.comRenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call TranscriptMay 15, 2025 | seekingalpha.comRenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2025 | zacks.comRenovoRx Reports First Quarter 2025 Financial Results and Business HighlightsMay 15, 2025 | businesswire.comEarnings Preview For RenovoRxMay 14, 2025 | benzinga.comRenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21stMay 14, 2025 | finance.yahoo.comU.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy PlatformMay 6, 2025 | finance.yahoo.comJohns Hopkins Medicine lance le recrutement de patients pour l'essai clinique de phase III TIGeR-PaC en cours de RenovoRxApril 30, 2025 | zonebourse.comJohns Hopkins Medicine lance le recrutement de patients pour l'essai clinique de phase III en cours de Renovorx sur le Tiger-PacApril 29, 2025 | zonebourse.comJohns Hopkins rejoint l’essai TIGeR-PaC de RenovoRx sur le cancer du pancréasApril 29, 2025 | fr.investing.comJohns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical TrialApril 29, 2025 | finance.yahoo.comRenovoRx ramps up production of FDA-cleared RenovoCathApril 18, 2025 | uk.investing.comRamtin Agah Purchases 15,000 Shares of RenovoRx, Inc. (NASDAQ:RNXT) StockApril 18, 2025 | insidertrades.comLe directeur médical de RenovoRx, Agah Ramtin, achète des actions pour 13.500$April 18, 2025 | fr.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMRN, MRSN, RNXT, and AADI Company DescriptionsAadi Bioscience NASDAQ:AADI$1.80 +0.04 (+2.27%) As of 05/27/2025Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.Immuron NASDAQ:IMRNImmuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.Mersana Therapeutics NASDAQ:MRSN$0.37 +0.01 (+1.64%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$0.37 +0.00 (+0.03%) As of 06:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.RenovoRx NASDAQ:RNXT$1.30 +0.06 (+4.44%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$1.40 +0.11 (+8.49%) As of 06:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
